# Claims

~~[Claim 1] A pharmaceutical formulation, comprising at least one antibody selected from:~~

~~(i) an antibody which comprises a heavy chain variable region that comprises CDR1 comprising the sequence of SEQ ID NO: 4 (CDR1 of VH3-M73), CDR2 comprising the sequence of SEQ ID NO: 5 (CDR2 of VH3-M73), and CDR3 comprising the sequence of SEQ ID NO: 6 (CDR3 of VH3-M73), and a light chain variable region that comprises CDR1 comprising the sequence of SEQ ID NO: 13 (CDR1 of VL3), CDR2 comprising the sequence of SEQ ID NO: 14 (CDR2 of VL3), and CDR3 comprising the sequence of SEQ ID NO: 15 (CDR3 of VL3);~~

~~(ii) an antibody that comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 20 (variable region of VH3-M73) and a light chain variable region comprising the sequence of SEQ ID NO: 23 (variable region of VL3); and~~

~~(iii) an antibody that comprises a heavy chain comprising the sequence of SEQ ID NO: 26 (VH3-M73) and a light chain comprising the sequence of SEQ ID NO: 29 (VL3);~~

[Claim ~~2~~1] A stable pharmaceutical formulation ~~according to any one of claim 1,~~ comprising 1 - 500 mM histidine and/or citrate buffer, 1-1500 mM of at least one cationic amino acid, 1-200 mg/mL antibody, and 1-400 mM of a carbohydrate, wherein the antibody is at least one antibody selected from:

(i) an antibody which comprises a heavy chain variable region that comprises CDR1 comprising the sequence of SEQ ID NO: 4 (CDR1 of VH3-M73), CDR2 comprising the sequence of SEQ ID NO: 5 (CDR2 of VH3-M73), and CDR3 comprising the sequence of SEQ ID NO: 6 (CDR3 of VH3-M73), and a light chain variable region that comprises CDR1 comprising the sequence of SEQ ID NO: 13 (CDR1 of VL3), CDR2 comprising the sequence of SEQ ID NO: 14 (CDR2 of VL3), and CDR3 comprising the sequence of SEQ ID NO: 15 (CDR3 of VL3);

(ii) an antibody that comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 20 (variable region of VH3-M73) and a light chain variable region comprising the sequence of SEQ ID NO: 23 (variable region of VL3); and

(iii) an antibody that comprises a heavy chain comprising the sequence of SEQ ID NO: 26 (VH3-M73) and a light chain comprising the sequence of SEQ ID NO: 29 (VL3).

[Claim ~~3~~2] The formulation according to claim ~~2~~1, whereby the cationic amino acid is arginine.

[Claim 43] The formulation according to claim ~~2~~-1 or ~~3~~2, whereby the carbohydrate is sucrose or trehalose.

[Claim ~~5~~4] The formulation according to any one of claims ~~2-4~~1-3 further comprising a surfactant.

[Claim ~~6~~5] The formulation according to any one of claims ~~2-4~~1-3 containing the antibody in an amount of at least 10 mg/ml.

[Claim ~~7~~6] The formulation according to any one of claims ~~2-4~~1-3 containing the antibody in an amount of at least 50 mg/ml.

[Claim ~~8~~7] The formulation according to any one of claims ~~2-4~~1-3 containing the antibody in an amount of at least 80 mg/ml.

[Claim ~~9~~8] The formulation according to any one of claims ~~2-4~~1-3 having a pH in the range from 4.5 to 7.0.

[Claim ~~10~~9] The formulation according to claim ~~9~~8 having a pH range from 5.5 to 6.6.

[Claim ~~11~~10] The formulation according to any one of claims ~~2-4~~1-3, whereby the formulation is liquid.

[Claim ~~12~~11] The formulation according to claim ~~11~~10 which has not been subjected to lyophilization during preparation of the formulation.

[Claim ~~13~~12] The formulation according to any one of claims 1-~~12~~11, wherein the dimerization of the antibody molecules is reduced.

[Claim ~~14~~13] The formulation according to any one of claims 1-~~13~~12, wherein the dimerization of the antibody molecules is inhibited.

[Claim ~~15~~14] The formulation according to any one of claims ~~2-4~~1-3, which is for subcutaneous administration.

[Claim ~~16~~15] A method for stabilizing an antibody during freeze/thaw cycles of a solution containing the antibody, comprising adding at least one cationic amino acid, wherein the antibody is at least one antibody selected from:
(i) an antibody which comprises a heavy chain variable region that comprises CDR1 comprising the sequence of SEQ ID NO: 4 (CDR1 of VH3-M73), CDR2 comprising the sequence of SEQ ID NO: 5 (CDR2 of VH3-M73), and CDR3 comprising the sequence of SEQ ID NO: 6 (CDR3 of VH3-M73), and a light chain variable region that comprises CDR1 comprising the sequence of SEQ ID NO: 13 (CDR1 of VL3), CDR2 comprising the sequence of SEQ ID NO: 14 (CDR2 of VL3), and CDR3 comprising the sequence of SEQ ID NO: 15 (CDR3 of VL3);
(ii) an antibody that comprises a heavy chain variable region comprising the sequence of SEQ ID NO: 20 (variable region of VH3-M73) and a light chain variable region comprising the sequence of SEQ ID NO: 23 (variable region of VL3); and
(iii) an antibody that comprises a heavy chain comprising the sequence of SEQ ID NO: 26 (VH3-M73) and a light chain comprising the sequence of SEQ ID NO: 29 (VL3).